Skip to content

PTSD: all studies

Page 144 of 210: studies 1,431 to 1,440 of 2,096, newest first. Back to the PTSD overview

Research

Impact of heartfulness meditation practice compared to the gratitude practices on wellbeing and work engagement among healthcare professionals: Randomized trial.

PLoS One 2024 Kunal R Desai, Patricia O'Malley, Emily Van Culin

To investigate whether Heartfulness meditation practice, compared to Gratitude practice, leads to measurable changes in mental wellbeing among healthcare providers across the US. Participants were randomly assigned to one of the following 6-week interventions: the trainer-guided virtual Heartfulness meditation program or the podcast-based self-guided gratitude practice group. The Professional...

Tele-Mindfulness Program for Mental Health in Previously Hospitalized COVID-19 Patients: A quasi-experimental study.

Advances in rehabilitation science and practice 2024 Giada Milani, Luigi Zerbinati, Luigi Grassi et al. 2 citations

Nearly half of subjects after COVID-19 still experience symptoms after 12 weeks, as described in the Post-Covid Syndrome (PCS). Other than the physical alterations perceived, mental health disorders have been frequently reported. Mindfulness-Based Interventions (MBIs) showed beneficial effects on psychological well-being in patients with respiratory dysfunctions, but they have been rarely...

DOI: 10.1177/27536351241308176 (opens in new tab) Full text (opens in new tab) Mindfulness Covid-19; tele-rehabilitation Mental health Psychological well-being

Hepatic injury and hepatic failure adverse events in 3,4-methylenedioxymethamphetamine users reported to the FDA Adverse Event Reporting System.

Frontiers in Psychiatry 2024 Tigran Makunts, Ruben Abagyan 2 citations

3,4-Methylenedioxymethamphetamine (MDMA) is being investigated in controlled clinical trials for use as an adjunct medication treatment for post-traumatic stress disorder. MDMA is metabolized by N-demethylation, primarily by CYP2D6, to its main inactive metabolite, 4-hydroxy-3-methoxymethamphetamine. It is also metabolized to a lesser extent by CYP1A2, CYP2B6, and CYP3A4 to its active...

DOI: 10.3389/fpsyt.2024.1414622 (opens in new tab) Full text (opens in new tab) Molly Ddi drug-drug interaction Faers MDMA 3,4-Methylenedioxymethamphetamine +5

A novel framework for ketamine-assisted couple therapy.

Frontiers in Psychiatry 2024 Chandra Khalifian, K Rashkovsky, E Mitchell et al. 8 citations

Intimate relationship distress is prevalent and is associated with poorer health, mental health, and mortality outcomes. Evidence-based couple therapies target cognitive, behavioral, and emotional processes that underlie relationship dysfunction. Increasing research and clinical evidence supports the efficacy of ketamine-assisted psychotherapy (KAP) for addressing clinical mental health...

DOI: 10.3389/fpsyt.2024.1376646 (opens in new tab) Full text (opens in new tab) Psychedelic therapy Couple therapies Ketamine-assisted psychotherapy Psychedelic therapies +6

Voice hearing in refugees survivors of traumatic events

Torture Journal December 28, 2023 Alberto Barbieri, Federica Visco‐Comandini, Danilo Alunni Fegatelli et al.

Introduction: Voice hearing (VH) is commonly associated with psychosis but it has also been reported in PTSD. The aim of this cross-sectional study was to identify the prevalence of VH in a sample of 110 treatment-seeking trauma-affected refugees, and to examine the relative role of certain interpersonal traumatic events (i.e., torture, inprisonment, sexual assault, non-sexual assault), PTSD...

Psychedelic Therapy: A Primer for Primary Care Clinicians – Part V. Ibogaine

December 26, 2023 Kirsten Cherian, Kenneth Shinozuka, Burton J. Tabaac et al. preprint

Background: Ibogaine is a plant-derived alkaloid that has been used for thousands of years in rites of passage and spiritual ceremonies in West-Central Africa. In the West, it has primarily been used and studied for its anti-addictive properties and more recently for other neuropsychiatric indications, including post-traumatic stress disorder (PTSD), depression, anxiety, and traumatic brain...

Psychedelic Therapy: A Primer for Primary Care Clinicians – Part I. Historical Perspective and Overview

December 26, 2023 Burton J. Tabaac, Kenneth Shinozuka, Alejandro Arenas et al. preprint

Background: Psychedelic drugs have recently emerged as plausibly effective pharmacological agents for the management of depression, anxiety, and other neuropsychiatric conditions, including conditions that have not benefited from prior interventions. The latter half of the twentieth century marked a revolution in the treatment of depression, anxiety, and psychosis, exemplified by the...

Association Between Psychotic and Dissociative Symptoms: Further Investigation Using Network Analysis

Journal of Trauma & Dissociation December 20, 2023 H. Fung, M. Wong, Andrew Moskowitz et al.

ABSTRACT The association and overlap between psychotic and dissociative phenomena have been increasingly recognized. Previous studies found that psychotic symptoms are closely associated with post-traumatic and dissociative symptoms and that these trauma-related phenomena may mediate the relationship between trauma and psychotic symptoms. It remained less explored which specific post-traumatic...

Ancient shamanic emotional healing techniques and today’s philosophical counseling

Interdisciplinary Research in Counseling, Ethics and Philosophy - IRCEP December 20, 2023 Daniela Stănciulescu 1 citation

In shamanic thinking, an important idea is that the earth does not belong to us. Earth is just a wonderful and welcoming host for us and other species. Did the sense of ownership dehumanize us, as the French philosopher Jean Jacques Rousseau would observe? Maybe. Lust for wealth, greed, and selfishness, these traits specific only to human people, among all inhabitants of our planet led, over...

Psilocybin facilitates fear extinction in mice by promoting hippocampal neuroplasticity.

Chinese medical journal December 20, 2023 Yingjie Du, Yunfeng Li, Xiangting Zhao et al. 71 citations

Posttraumatic stress disorder (PTSD) and depression are highly comorbid. Psilocybin exerts substantial therapeutic effects on depression by promoting neuroplasticity. Fear extinction is a key process in the mechanism of first-line exposure-based therapies for PTSD. We hypothesized that psilocybin would facilitate fear extinction by promoting hippocampal neuroplasticity. First, we assessed the...

DOI: 10.1097/cm9.0000000000002647 (opens in new tab) Full text (opens in new tab) Psychedelics Mental health PTSD Treatment Fear response